Cambium Bio Ltd Cash Flow Conversion Efficiency
Cambium Bio Ltd cash flow conversion efficiency. Based on the latest financial reports, Cambium Bio Ltd (CMB) has a cash flow conversion efficiency ratio of -1.444x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-2.65 Million ≈ $-1.88 Million USD) by net assets (AU$1.84 Million ≈ $1.30 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cambium Bio Ltd (1999–2025)
Cash flow conversion efficiency of Cambium Bio Ltd from 1999 to 2025. This chart illustrates how Cambium Bio Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Cambium Bio Ltd for real-time trading data and today's change.
Cambium Bio Ltd Cash Flow Conversion Ratio Explained
Cambium Bio Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cambium Bio Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cambium Bio Ltd ranked by their cash flow conversion efficiency. Also see Cambium Bio Ltd (CMB) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Diamond Citra Propertindo PT
JK:DADA
|
0.018x |
|
Fab-Form Industries Ltd.
V:FBF
|
0.059x |
|
Together Startup Network Ltd
TA:TGTR
|
-0.149x |
|
DTI Group Ltd
AU:DTI
|
-0.075x |
|
ADX Energy Ltd
AU:ADX
|
-0.118x |
|
Cohort
LSE:CHRT
|
0.229x |
|
Renoworks Software Inc
V:RW
|
5.279x |
|
Bima Sakti Pertiwi Tbk PT
JK:PAMG
|
0.004x |
Annual Cash Flow Conversion Efficiency for Cambium Bio Ltd (1999–2025)
The table below shows the annual cash flow conversion efficiency of Cambium Bio Ltd from 1999 to 2025. Review CMB free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$1.84 Million ≈ $1.30 Million |
AU$-5.24 Million ≈ $-3.71 Million |
-2.856x | -4986.40% |
| 2024-06-30 | AU$2.78 Million ≈ $1.96 Million |
AU$-155.86K ≈ $-110.28K |
-0.056x | -116.58% |
| 2023-06-30 | AU$-1.95 Million ≈ $-1.38 Million |
AU$-660.46K ≈ $-467.32K |
0.339x | +110.13% |
| 2022-06-30 | AU$1.07 Million ≈ $760.48K |
AU$-3.59 Million ≈ $-2.54 Million |
-3.341x | -672.70% |
| 2021-06-30 | AU$4.15 Million ≈ $2.93 Million |
AU$2.42 Million ≈ $1.71 Million |
0.583x | +132.85% |
| 2020-06-30 | AU$1.09 Million ≈ $774.10K |
AU$-1.94 Million ≈ $-1.37 Million |
-1.776x | -414.34% |
| 2019-06-30 | AU$-6.39 Million ≈ $-4.52 Million |
AU$-3.61 Million ≈ $-2.55 Million |
0.565x | +138.87% |
| 2018-06-30 | AU$2.92 Million ≈ $2.07 Million |
AU$-4.25 Million ≈ $-3.01 Million |
-1.454x | -428.22% |
| 2017-06-30 | AU$8.10 Million ≈ $5.73 Million |
AU$3.59 Million ≈ $2.54 Million |
0.443x | +194.04% |
| 2016-06-30 | AU$4.78 Million ≈ $3.39 Million |
AU$-2.25 Million ≈ $-1.59 Million |
-0.471x | +34.23% |
| 2015-06-30 | AU$8.27 Million ≈ $5.85 Million |
AU$-5.92 Million ≈ $-4.19 Million |
-0.716x | +4.65% |
| 2014-06-30 | AU$8.31 Million ≈ $5.88 Million |
AU$-6.24 Million ≈ $-4.41 Million |
-0.751x | -146.66% |
| 2013-06-30 | AU$-2.87 Million ≈ $-2.03 Million |
AU$-4.62 Million ≈ $-3.27 Million |
1.610x | +206.69% |
| 2012-06-30 | AU$1.95 Million ≈ $1.38 Million |
AU$-2.94 Million ≈ $-2.08 Million |
-1.509x | -372.04% |
| 2011-06-30 | AU$3.29 Million ≈ $2.33 Million |
AU$-1.05 Million ≈ $-743.44K |
-0.320x | -338.79% |
| 2002-06-30 | AU$40.54 Million ≈ $28.68 Million |
AU$5.43 Million ≈ $3.84 Million |
0.134x | -31.25% |
| 2001-06-30 | AU$196.21 Million ≈ $138.83 Million |
AU$38.20 Million ≈ $27.03 Million |
0.195x | -35.02% |
| 2000-06-30 | AU$161.09 Million ≈ $113.98 Million |
AU$48.26 Million ≈ $34.15 Million |
0.300x | +17.02% |
| 1999-06-30 | AU$130.56 Million ≈ $92.38 Million |
AU$33.43 Million ≈ $23.65 Million |
0.256x | -- |
About Cambium Bio Ltd
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing i… Read more